Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10011228HBVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30005072HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30005073HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30001457HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30011160HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30014456HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30011161HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30005074HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30001458HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TVIS30011162HIVENSG00000171608.18protein_codingPIK3CDYesNo5293O00329
TCGA Plot Options
Drug Information
GenePIK3CD
DrugBank IDDB12483
Drug NameCopanlisib
Target IDBE0002406
UniProt IDO00329
Regulation Typeinhibitor
PubMed IDs30147333; 29127587
CitationsMensah FA, Blaize JP, Bryan LJ: Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018.@@Markham A: Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6.
GroupsApproved; Investigational
Direct ClassificationQuinazolinamines
SMILESCOC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
Pathways
PharmGKB
ChEMBLCHEMBL3218576